when you became ceo of merck, roughly three years ago, the statement you made you wanted merck to focuson. what does innovation look like at maybe? >> merck? >> well, for america, itmerck i forward with transitional medication. it's one of the first in a series of what are called immunotherapies for cancer. this medicine is one that actually helps the body's own national defenses defeat the tumors. that's the kind of thing the company like merck exists to do. >> how do you decide which drugs will be in the pipeline for long-term development. >> first of all, those decisions made by very capable research scientists. they are not made in the first instance by me. that's the good thing for people, investors as well as patients that they are made by those very able people. generally speak where merck tries to go with research dollars, we look for unmet need and scientific opportunity. we want to be in areas like cancer, like alzheimer's, like hiv, like hepatitis c. where there is a medical need around the world. and where we have scientific opportunity in terms of new targets that we can go

merck to focus on innovation.ok like at merck? >> well, for merck, coming forward with transformational medicine. a recent example is our new investigational medicine for cancer. it's one of the first in a series of what are called immunotherapies for cancer. it defeats the body defeat the tumors. that's the kind of thing a company like merck exists to do. >> how do you decide which drugs are going to be in the pipeline for long-term development? >> first of all, those decisions are made by our very capable research scientists. they're not made in the first instance by made. and that's a good thing for people, that they're investors as well as patients being made by those very able people. but generally speaking, where america tries to go with its research dollars, we look for the intersection of unmet medical need and scientific opportunity. so we want to be in those areas like cancer, like alzheimer's, like hiv, where there's great unmet medical need around the world, a need for better therapy, and where we have

of merck.t struck me there in the merck interview is this is a company that should be taking advantage of the weaker euro and stronger dollar. it doesn't fit r through to the bottom line. when people say buy companies with exposure to the u.s. and get the benefit. is that really the case? >> in that particular example, clearly not. we're expecting companies to be hedging policies. in has been a change in the euro in the last six months. the immediate currency move is really washed through in terms of the account. if the euro continues lower and they choose not to put future hedges on that would be the time to see the benefit. >> on the funding environment here in europe, the funding environment is easy, easy, easy. low rates for issuing corporate bonds. some at record low interest rates. what are you seeing now? >> if you're a large european, especially german corporate, it is a great generation of opportunity to be locking in low rates. if you're a household, not so good. e still have this div

pfizer and merck not the only players. roche and bristol myers are l k looking into this therapy. >> we'll talk about this more but still a lot of deals to be done in the health sector. >> i think it is a partnership. the leading cause of death right now in the u.s., heart disease is number one, cancer is number two. so clearly a growing need for medicines and treatments to combat cancer. >> indeed. and news of another deal in the health care sector. activists reportedly are nearby after earning up to 62.5 billion that could end up in pursuit from activists. they could pay between $215 to $220 a share. a deal could be announced later today despite the current 4 billion dollars. >>> and allergan and valent pharma are both up this morning. >>> and find out who is piling into the al alibaba shares. >>> and speaking of trust, would you be happy to use facebook at work? stay tuned to weigh in on the viewer exchange. >>> the g20 leaders in australia has wrapped up with commitment to boost global growth and tackle climate change

with merck involved the drug's development could move at a faster pace. still merck shares fell a little bit today to 49.25. >>> and lockheed martin won a nearly $5 billion government contract and that sent shares up slightly. the deal is with the pentagon to supply an eighth batch of those very pricey f-35 fighters. the stock was 89 cents higher to 188.82. >>> a big sell-off of shares in trina solar. its quarterly results also missed expectations. shares slumped more than 5% to $10.36. >>> a unit of citicorp must pay a fine for lapses in supervision. the financial industry regulatory authority found that the company failed to adequately supervise its research analysts' interactions with bank clients. the bank neither admitted for denied the charges but consented to the finding. shares rose 1 1/2% to 54.40. >>> renting redbox movies is about to get more expensive. the owner of redbox kiosks, outerwall, is hiking the prices for renting movies and games to help fund improvements in its business as streaming sites are reducing demand for dvds. they'll be $1.

we have a great interview with the ceo of merck after pfizer is buying merck's cancer drug rights for0 million. that interview is after the short break. >> welcome back to "the pulse." i am francine lacqua. the british prime minister david cameron has warned instability in europe presents a risk to the u.k. economy. cameron said that eurozone is teetering on the brink of a recession and britain would continue to use the monetary policy to support growth without adding to borrowing or data. president barack obama has called the beheading of aid afct --eter kassig, an act of pure evil. here's the sixth that he is a the sixth foreign -- if this is for there to be beheaded by isis. six -- heis a these sixth foreigner to be beheaded by isis. the nikkei closed down almost 3% on the news. , let's walkt japan on the economy editor for japan bloomberg. does it mean for i'm a nymex? -- four abenomics? advisers said it was a body blow for abenomics. the sales tax increase has to be postponed and he is back in japan for the g-20 australia and have a press conference tomorrow and we'll talk about

pfizer will pay merck $850 million up front for a percentage of sales. the drugmaker also lowered its 2014 outlook in part. >>> yet another possible merger that was reportedly in the discussion stage last week has apparently broken down. "the wall street journal" says that deal talks between dreamworks animation and the toymaker hasbro have hit a major snag over the structure of the combined company and that those talks are not likely to resume. hasbro shares weren't playing around today. rising more than 4%. but the curtain really did come down on shares of dreamworks. they lost 14%. >>> on wall street today, stocks traded in a narrow range of gains and losses despite all that merger activity and expectations for additional stimulus measures in europe and japan. the dow added 13 points, the nasdaq was down 17 and a one point gain in the s&p was just enough to notch a new record high. >>> more now on japan. it's the latest global economy getting weaker instead of stronger. today japan reported really terrible economic data despite massive, even unprecede

. $80 million up front for sharing rights of merck's immunotherapy treatment.here is also a prospect for extras in a cup. -- astrazeneca. and a deal over allegan could be worth up to 60 by billion dollars. -- $65 billion. the company is said to be secretly working on it new professional networking site to allow users to separate their work profiles from the personal details. the project is named facebook at work. it allows connecting to professional contacts. >> oh, no, i like those cat videos. you need a little bit of lightness. any of us, sports are a favorite pastime or a means to get fit. but for the people you'll meet on this week's "full frame," sports have been a path to having a positive impact on the world and thriving in the face of obstacles. i'm mike walter in los angeles. let's take it full frame.

looking at the chart that mitchell's showed a miss thinking back to my days at merck. once you move through the development cycle, once you start to get some promising results which i think is where we are right now with broadly neutralizing antibodies, you are spending usually escalates dramatically. it may go up two or three fold. the fact the we are down 10%, 15% is worsened by the fact the we should be increasing exponentially and so we all have to work hard to make sure that story is heard and when we are ready to move forward with large-scale trials and manufacturing costs that the funding is there to support that. the organization was developed because global experts came together and said we need an organization that is solely dedicated to the development of an aids vaccine that can work with all the parties out there and be sure that happened. were it not for profit organizations funded to u.s. government or unaids and usaid and the gates foundation, our largest foundation donor the gates foundation and smaller foundation donors as well. so the role we try to

she spent 26 years, i believe, at merck. one of her jobs was to lead their efforts on the step trial, and another vaccine products america has led. she's also instrumental in reduce theirca to prices on delivering the into the products world, better than the previous mandela. suing nelson it's a really great opportunity to hear from someone who has been involved in industry and has taken a moment of her life to help us on an aids vaccine. margie, thank you for coming. >> thank you, todd. to mitchell's point, it's very difficult to first follow such an esteemed scientific leader, who's also an advocate, and an esteemed advocate who also knows a lot about the science. they are terrific colleagues to work within this field. i think the task at hand calls for the best of all disciplines to step forward. so the organization that i lead -- let's see, i don't have the right slides up here. here we go. the organization i lead is called the international aids vaccine initiative. many of you are familiar with the concept of product de

we look at how the deal and speed up merck.with us. ♪ >> welcome back. .his is on the move here are companies on the move. access to had services in the u.k. and they said it would improve the profitable business. carefully weighing the other banks. there is a says merger proposal so far. there was the ecb stress test. secretly developing a new website to take on linkedin. the website would be called "facebook at work." it would compete directly with google drive and microsoft office. prices rose 0.8% all stop house prices across the u.k. fell ahead of the seasonal winter slowdown. prices curbntum as demand. one of thehing biggest movers in early trading that has agreed to pay $850 million for the right for a cancer drug developed by merck. sam, investors think this is a good deal. let's talk about the price. >> there are assets that are attractive. this is a mechanism to deal with cancer and we have not seen many so far. it has been on the market for while. is what pfizer is signaling. they need to be in the space. it is going

she spent 26 years i believe at merck. whenever jobs was to lead their efforts on the step drop, and other vaccine product that mark hazlett. is also rich in and getting merck to reduce its prices for delivering its anti-retroviral component into the developing world, better than the previous one of suing nelson mandela. so it's a really great opportunity to from someone who's been involved in industry and now has taken a moment of her life to help us on an aids vaccine by leading. margie, thank you very much for coming. >> thank you, todd. and to mitchell's point, it's very difficult to forestall such an esteemed scientific leader was also an advocate, and an esteemed advocate who also knows a lot about the science. there are terrific colleagues who work with in this field, and to think the task at hand calls for the best of all disciplines to step forward. and so the organization that i lead, let's see -- i don't have the right slide of your. every go. your position i lead is called the international aids vaccine initiat

merck is not an expensive stock. i kept listening to david pyott and what brent saunders created.s merck and pfizer, everybody a run for the money. >> interesting to note, actavision share up this morning, people going into this would not have expected if you pay $219. >> 219 is not an expensive price. >> you believe that? >> i'm telling you, what they've got in the pipe line is revolutionary, what they can do with botox. i can't say they can double sales in three years but discoveries and uses off label that people only dream of and haven't capitalized on them yet. >> six years ago, botox the only thing terms of consumer cosmetics, all we talked about. >> wrinkles are a minor business in 2016. you won't believe it. the most controversial stock i've ever had on, globalstar, the ceo is coming on. i was call calling it a battleground. he begs to differ. it's a very big long. i think people are going to want to watch this interview. this is $2 stock where if you don't want "mad money" you have no idea what to do with this. if you like what he has to say, double or nothing. >> i'm the

my charitable trust tried to buy merck. finally, for the tech theme of mobile social cloud and connectivity look no further than alibaba. the amazon of china. something amazon may never have bountiful profits. today is not only the eve of veterans day but the eve of singles day in china. alibaba rallied $4.59 a day. this is one big deal of the day. alibaba no inventory online business model, excellent mobile offering may just justify its amazing move from $68 to $119 and change today. it is now bigger than wal-mart. i said this stock would go to 120 valued similar to facebook and urge you to play to yahoo. a good singles day and i have to bump my 120 target a hair above where it went out today. i'm thinking double since coming public. here is the bottom line. i always say default to the big go-to themes. natural and organic food, bio tech stocks. buy them when you can when the short termers give you a chance. given how the hedge funds seem to buy high and sell low they can be an annuity for those with a time horizon longer

she spent 26 years, i believe, at merck. one of her jobs was to leave -- leader their adverts -- was to leave their efforts on trials. it's a really great opportunity to hear from someone who has been involved in industry and has taken a moment of her life to help us on an aids vaccine. margie, thank you for coming. >> thank you, todd. to mitchell's point, it's very difficult to first follow such an esteemed scientific leader, who's also an advocate, and an esteemed advocate who also knows a lot about the science. they are terrific colleagues to work within this field. i think the task at hand calls for the best of all disciplines to step forward. lead --nization that i let's see, i don't have the right sides appear. here we go. the organization i lead is called the international aids vaccine initiative. are familiar with partnerships. and there were anywhere between 13 to 15 depending on how you define the term, of these types of organizations that were started primarily from the mid-1990's through the early 2000 and they w

i focused on our customers like merck, mci, something where we could get immediate global one, freddie --ticipated, and ask them actually i wrote a proposal to them saying, fund this and we will give you so many licenses. >> unanet software is constantly being updated and d specialized. her team is a strong one. it is like family, literally. she has watched heher son move p to the rags to be a top salesman. >> people ask me all the timee what it is like working with my mom here and i have a direct relationship with my mother, so it is like working when it -- with one of your best friends. >>mom here and our revenues are% a year. that is pretty good. >> the company is a success by most measures and is not beholden to anyone except its customers. .> unanet is also funded there is no private equity, no venture capital. to be frank, there is no real interest in taking that on right now. it has been a decision that we made to focus on the growth of the company. we have invested in ourselves rather than taking on outside capital. the important thing about that is it allows us to focus on our

merck can't spend $3 billion on every good idea.ike this that's shown some success come up with one more, and this bad boy becomes a major, major talkover -- >> it's a great trend for me, the chart's fantastic, and fundamentally look at the earnings projectionings. almost $6 a share from $1.41. there's a lot of potential in this one, charles. i love it long term. charles: i'm feeling pretty good about it. >> i like what you said about the smaller company versus the larger company. we see this a lot in business because big companies are looking to partner with these smaller companies because they can move faster, they're more innovative, and that's what makes this a good bet. >> i tell you, we don't need antitrust regulations. whenever you hear that, we're like we don't need it. how many people don't know that a and p, the supermarket mostly on the east coast at one point controlled 70% of the food. congress was ready to break these guys up. they didn't have to, it didn't matter. it's about these big, lumbering giants to partner with

san francisco's ross merck knee knee was there. >> there were many meetings we had with ted. >> he died suddenly at his home last month. there was no word on a cause of death. >>> san francisco police are launching a media campaign to warn the chinese community about so-called blessing scams. [speaking in foreign language] the department released this public service announcement in cant these. convince the target that cash and valuables must be offered in exchange. there have been reports of two recent incidents. >>> now this was in canada last july. a 74 car train carrying crude oil derailed killing 42 people. the kind of crude ail oil it was carrying is called backen. it's known to be more volatile and being transported by rail. even more crude oil is being transported by rail. but the state receives very little information about the schedules and when the crude oil trains are coming and going through bay area neighborhoods. >> just like when you would know where an amtrak train is, we should be able to know that about volatile substances. >> tonight at 10:00, 2 investigates uncovers

pete in pfizer and merck. >> and bristol and lily.ck with the cholesterol drug that stock on the move. >> yeah. >> you heard what he said about pfizer. give me your take. >> when you look at these names talking about names everybody loves it use the word defensive. i never viewed them as defensive. either they're growth or not. they've been growth, valuations solid and they've been able to put themselves in a position to make some of these big takeouts. does it have to be 100 plus billion. i don't know that it does. one thing mark said what if it's a multiple deal far less, $20 billion, versus the $100 billion. there's an upside in all of these names. >> coming up, thank you by the way, kate, could this be marissa mayer's time to shine. investors waiting and watching for the yahoo! ceo for something to happen. this friday pay be a now or never moment. eric jackson live after the break to tell us why. is hasbro's hollywood dream over? the latest on the talks to bring dreamworks studio into the toy giant's portfolio. we're back in a cou

pfizer is going to buy the rights of a cancer drug developed by merck, and they can expect a paymentf more than 2 billion euros. the shares have been on the highest level ever. >> in frankfurt we have a quick look at monday's numbers. euro stoxx 50, doing even better on wall street at this hour. the dow, trading at a level of 17 645, just barely up in positive territory, the euro trading down. >> british health authorities are looking to identify a strain of bird flu detected on a farm in northern england. >> officials are calling all the birds on the premises. on sunday this strain of the bird flu was found on a poultry farm in the netherlands. >> a state-of-the-art research ship has been delivered to german scientists. it is the world's most modern scientific research vessel. >> eight laboratories on board, it will search the oceans for rare raw materials. >> the 116 meter long research vessel is one of the most modern ships in the world. up to 40 scientists on board will record data from the depths of the world's oceans. as i >> it will provide information on the climate and clima

. >> analysts also expect data from competitors advee and merck and particularly are watching to cut treatment times to as much as four weeks. but hepatitis c is not the only focus, two other liver diseases have been capturing the attention. >> hepatitis c i would argue remains the focus because it is so commercially near term. we're just seeing these massive sales stickers right now. people are looking to the future to say hey is there anything else beyond hepatitis c? >> and those markets, analysts say, are as big or bigger than hepatitis c. but efforts to treat the disease that can lead to scarring, and hepatitis b. companies working with gill i add are smaller like intercept. >> analysts say it could be years before we see other drugs have as much progress as hepatitis c. for "nightly business report," i'm meg turrell. >>> coming up, shippers are expecting a record season but is everybody read >>> the u.s. postal service is ramping up for the holidays, saying they will add sunday deliveries in major metropolitan areas starting november 17th and running right through christmas day

among the companies to hire, amtrak, lock he'd martin, merck & company and pse & g. >>> and workers will be paid at least $10.10 an hour starting in january. >>> and nfl player devon still will have a special stand in the stands tonight. we gave you a preview last night. his little girl leah will be there to cheer him on. >> leah's been battling cancer here at children's hospital of philadelphia and tonight she'll be the guest of honor. between the first and second quarter of the game the bengals will present a check to cincinnati's children's hospital in leah's honor. that money will go towards pediatric research. >> in the interview, he said that his daughter knew that his job is to knock people down. that's what she's cheering for. >>> you're watching "nbc10 news." "nbc10 news" at 5:00 a.m. starts right now. >> announcer: nbc10 breaking news. >>> back in philadelphia, while you were sleeping, a woman abducted from a philadelphia street left a hospital with her family. carlesha freeland-gaither was found live just hours later in maryland. also new this morning, the suspect's dad is tal

among the companies looking to hire, amtrak, lockheed martin, merck and pse and g. >>> federal doughnuts is looking to expand outside of philadelphia. ppl is cutting jobs and israeli startup is planning to stay in philadelphia. you can read more of those stories in today's philadelphia business journal. >>> well, the market is reacting to this week's midterm elections. bertha coombs is here with this morning's cnbc news. bertha, good morning. >> good morning, tracy. we've got futures pointing to a lower open after stocks entered mostly higher on wednesday. that's reaction to mixed economic news and midterm election results. the dow, the s&p 500, the dow transports and the utilities indexes all closing at record highs. that's the first time that's happened all on the same day in more than 16 years. >>> today, we're going to be watching for data on unemployment claim. that's about 8:30. also worker productivity and labor costs. that could set the tone for the rest of the morning. >>> the airline industry expects more than 24 million passengers to travel over the thanksgiving holiday period

plenty of interesting, smaller biotechs out there for merck just so we're clear, my charitable trustthat for other reasons. very big drugs in the pike. if you're selling stock, be careful. these are -- some of these -- this bristol-myers, some older line companies have more game than you think. but gilead is doing a lot right, celgene is doing a lot right. regeneron, and argala, regeneron. >> dendreon, filing for chapter 11. >> a situation where retail investors became fascinate the with the drug provenge and it didn't work. it didn't price work. you have to recognize whether the diet pill, something that is just kind of looks like it's the magic bullet for the diseases, there are no magic bullets other than gilead's hep c. it cures. >> 180 million people around the world? >> it's been one of the things where the insurance companies are praying for alternative. they just keep thinking, if we can pit gilead against someone, if we can make it gilead doesn't have a monopoly, but a lot of the guys, listen, we're not paying but it's hard not to pay for a cure. it's a fatal disease. >> it

george merck. his name may sound familiar because there's a billion-dollar multinational pharmaceutical company named after him. but he was the american oppenheimer for the offensive bw program. quite frankly during the several years it was existent in world war ii, they were never able to create a functional biological weapon that they intended to use at either japan or germany used those weapons against us. i make that point because there's an historical point about the role of intelligence. in 1943, when president fdr was warned about the possibility of biological warfare, the u.s. intelligence community, basically informed him germany had a biological weapons program and germany didn't. we found out after the war the exact opposite was true. you can relate to more recent examples where the intelligence community hasn't been 100% right on these sets of issues but it's just worthy to note it was certainly the case then and now if we rely on intelligence we may be very disappointed. particularly a

a judgment by the name of george merck. is me me simply because there's a billion dollar multinational pharmaceutical company named after him but he was the american oppenheimer for the offensive bw program. quite frankly during the summer years that it was in existence in world war ii quite frankly they were never able to train a functional biological weapon that they intended to use had either japan or germany use those kinds of weapons against us. i only make that point because i think there's a historical point about the role of intelligence. in 1943 when president fdr was one of the possible biological warfare, the u.s. intelligence community basically informing german had a biological weapons program and japan didn't. we found after the war the exact opposite was true. you can probably relate to a more recent example with intelligence community has not been 100% right on these issues but i think it's worthy to note it was the case then and now that in some ways if we relied on intelligence we may be very disappointed.

biologicalas also a oppenheimer, a gentleman by the merck, his name may sound familiar because there's a billion dollar pharmaceutical company named after him. but he was the american for --imer quite frankly they never were able to create a functional biological weapon that they intended to use at either japan germany used this is kind of weapons against us. i only make that point because i there's a historical point about the role of intelligence, in 1943 when president f.d.r. was warned about the logical warof buy pair and the u.s. intelligence community basically informed him germany had a buy logical weapons program and japan didn't. after the war the exact opposite was true. probably relate to more recent examples where the hasn't beenunity 100% right on these issues, but i think it's wore any to note case then ande now that in some ways if you spellings we may be disappointed. andicularly about terrorism disease itself. the point i'm trying to make is merck released a report to the american public about the efforts to develop biological weapons. cases that ihe few know of where

a blockbuster drug that limits these mutations, it's sold by merck along with north medication.ical basis that the drug could actually help. it was mostly funded by the national institutes of health. >>> karen rogers is here now with accuweather, the cooler temperatures have arrived. >> in some spots in the midwest 50 degrees below average and in our area not quite 10 degrees below average. we can complain though absolutely. stormtracker 6 live double scan showing we are dry but we'll use it because we are tracking rain tonight even a wet snowflake or two. lets go outside and sky 6 hd looking live in atlantic city, the clouds are hanging tough even along the coastline. along the coast we are looking at temperatures in the upper 40s, 46 in millville and the city, 45 in trenton and wilmington and in the low 40s right now in the lehigh valley. cool out there tonight and the windchill is making it feel cooler than that. satellite 6 along with action radar showing the past 12 hours, we have clear skies and the clouds are sticking with us and the precipitation is what is coming next a

you saw the check point pivoters at merck. vaccines coming out of the last conference are something that investors and physicians are looking for to be a key main stay for therpapeutictherapeuti we have another guest who is a health care investing veteran who stayed away long before the company's crumble. health care portfolio manager. the question is basically the same that is if you think staying away for quite some time what did you see as a warning that perhaps others on wall street did not? >> the most obvious they raised a lot of debt and a company with negative ebida is not able to service the debt which is a warning sign for other bio tech companies with debt. if you raised equity it might be a different story. even on earlier stages in terms of diagnostics have changed. so the world changed on them and they were overlevered. >> do you say it is a cautionary tale of others who have taken on debt. what others are out there that we should be worried about? >> i would say as a general rule any company without revenue and

the point i'm trying to make is in 1946 george merck rereesed a report -- released a report about biological weapons. it's one of the few cases i know of where a report was unclassified, released to the public, later classified as secret and pulled from all the shelf. why was that? it scared the bejesus out of the american public. it created a firestorm in print at that period of time, and you can recount that if you've ever been to the archives of "newsweek" mag chien and "time" magazine and actually evaluate what was not only the scientific debate, but the fear that was invoked by the concept that you could create agents that would be invisible, that would be, if you will, totally alien to our senses, that could ultimately kill you in a rapid fashion. i would argue you that everybody's been sick in their life, so there's some element of what i'd say personal reference to the idea of illness as it is. now, a few people have had ebola in america, but if you recall barbara preston's book, "the hot zone," certainly a compelling case why you should fear such an organism like ebola virus. so in

. >> when the merck was fulfill, i changed over to new york stock exchange and started talking to joebining a message fund together. i remember going into his loft one day and was like, where did you get the wine rack? and he said, i built it. >> i had done this because it was a release from trading. >> it began as one wine rack in my garage and driveway. one day i was trading and got a call from a guy in texas that he wanted to build a wine cellar. and he said, google. and i said, this is going to work. and then i started getting contacted from all over the world. we looked at each other one day and said, we have outgrown my garage. not to mention my wife was going to strangle me. and it just became what we did instead of trading. >> we, by no means, were the first people to design a wine cellar but we took it to a different level. we did a 5,000 bottle wine cellar and then 10,000. could we do 20,000? we can do anything and never back away from a design challenge. >> i never felt like i had a business when i traded. here we are building something tangible. >> love that. joseph and ku

pfizer, merck. and technology, apple and microsoft. the names on that list. and the top ten you are going to find a lot of pharma and technology names. i think those will do very well. and that is going to be great for the u.s. economy. >> joe, quickly, keystone, the majority whip was on cnbc saying this first week the bill is going to be on the president's desk. >> there are a lot of things that potentially are going to be positive for the economy. repatriation of capital could be. all these initiatives don't have to hit. >> more than potentially. it ee's absolutely. >> yeah. and all these initiatives don't have to become actual policy it comes at the e perfect time. the perfect storm. we've all talked about the economy really not performing the way it's supposed to. now i think you have the chance for the economy to really accelerate domestically. how about this stat? the dow has not had a preelection year loss since 1939. so talking about 2015 historically setting up pretty darn well. >> and you heard paul richards last week just pounding the table for how

it's important because if, in fact, you can't deliver that gold, there's $3 billion on demand at the merckht now, if you need 3.1 billion, gold can go to -- [inaudible] so there's a reason to have it because there's not enough on demand at this point. everyone should have a little gold. charles: real quick, and you like the other metals as a proxy for the economy? >> look, silver's a great one, but at the same time silver's used for industrial purposes, so you get a double play there. >> i like gold corp., gg, which is based in vancouver, and i also like rand gold which is an african-based gold company, and it's so undervalued because of the ebola scare in places like the ivory coast. charles: matt, what do you make of the fact that gold is down to a four-year low, but gold stocks are a six-year low? a lot of people saying there's a play there. whether gold goes up, the stocks themselves, the might beer -- miners are oversold. >> they're not going anywhere, and that's not going to be before gold breaks $1,000 an ounce. >> the miners are so depressed concern. >> they were depressed when it

coming up next on "good morning america" merck that's right darren wilson breaks his silence.iew with george. meanwhile the protests continue across the country so we'll have the very latest details live from missouri and then i just heard you all talking about the blustery nor'easter wreaking havoc on holiday travel plans. we'll take a look at the weather hitting the east coast and how it will affect holiday travel nationwide. and then home security systems designed to keep you safe. see the three quick ways our expert tricked the system found in millions of homes and how you can stay safe. and then as our "dancing with the stars" after party. the stars and the winner of that coveted mirrorball trophy flying all light this morning to celebrate their dance moves we have balloons confetti all coming up next. >> fun. >> we'll take a break, come back to your top stories and go on to that. >> ♪ >> ♪ >> 6:55. action cam live at philadelphia international airport. where lines have been getting longer throughout the morning. the weather is conspiring to make the prethanksgiving day r

trust merck i have many coach chu-- ketchup-dribbled lips. a very good first day of trade.atulations, sir. >> thank you very much. >> care to respond, peak burger, a shakeout, something else? >> i kind of agree. i think the burger category is a huge category. it's historically dominated by traditional qsr players. the top four have over 30,000 locations just domestically. and the fast casual, which is an emerging category in better burger just fits lifestyles so much better. people are absolutely looking for fresher, better quality, made the-to-order. >> do you -- we talked about jack in the box yesterday. you are killing it, do you compete with jack in the box or have a different customer, hardee's, carl's, jr., mcdonald's? >> i think we compete with the legacy fast food brains but also taking share from them. but we are also taking share from the other side of the business the more full service category. y do you think you are taking share of them, because you're -- your option, we have a theory not really the healthy people after things. when i want a big, i want it dric

one of the things i hear in the power sector -- i was down in san antonio talking to merck last week. one of the challenges i think in the power sector and what i often hear from corporate leaders is you need to understand some of the constraints we work on. we are regulated industry. in order for us to generate income to make some of the changes we feel we need to do, we need to go to a regulatory body and make an argument. few of our citizens are interested in increased power rates as a vehicle to generate more money to address cyber security and our regulatory bodies share this concern. first, my thanks to the power sector for within those constraints try to push this as hard as we can. i have some real concerns in this arena. in terms of the kind of idea about how we can train and practice with each other -- one of the things i have said both internally within the department of defense as well as the private sector, individuals and organizations i deal with, we have got to move from a focus where almost all the resources focus on stopping someone penetrating our networks to an ack

but also competing is merck.stocks moving this morning where they're looking to shorten duration times to four weeks. that didn't quite hit the mark. >> we did an experiment to look at four weeks and six weeks and eight weeks. as it turns out, the four-week duration might be too short. that's much of an improvement compared to 12 to 24 weeks. >> now, there are two other liver diseases on investors' radar screens here. those are hepatitis "b" and n.a.s.h. bringing you interviews with some companies as well as updates from the meeting all throughout the day. >> thank you. we'll be looking forward to that. thanks. >>> time for today's trading block. we're going to focus on oil and currencies. the dollar up 9% this year with the gains made in the past three months. oil prices bounding back a bit after a deep slide the past few weeks. demand expected to get a blast expected to blanket a good chunk of the country. joining us is bk asset management and rbc capital markets. good to see you, ladies. ladies. can the winter

some of the dow winners include merck's, united health, boeing, pfizer. l toyo loco.he downside. total outstanding shares. jefferies raising jeffrey is raising zynga to a buy from a hold. reiterating the price target. also, new words with friends. much more varney and company coming up. ♪ and the aerospace industry in the u.s.? at t. rowe price, we understand the connections of a complex, global economy. it's just one reason over 70% of our mutual funds beat their 10-year lipper average. t. rowe price. invest with confidence. request a prospectus or summary prospectus with investment information, risks, fees and expenses to read and consider carefully before investing. hard it can be...how ...to breathe with copd? it can feel like this. copd includes chronic bronchitis and emphysema. spiriva is a once-daily inhaled... ...copd maintenance treatment... ...that helps open my airways for a full 24 hours. you know, spiriva helps me breathe easier. spiriva handihaler tiotropium bromide inhalation powder does not replace rescue inhalers for sudden symptoms. tell your doctor

cisco systems and ibm are two of the winners on dow jones industrial average, a new high today, nike, merckback. halliburton is in talks to buy baker hughes, both stocks are tacking on an yesterday's gains and that watchmaker came out with their numbers and third quarter results, they say, will miss the expectations that analysts put out there and grab weakness in their international markets. stock is down 30%. my goal was to take an idea and make it happen. i'm janet long and i formed my toffee company through legalzoom. i never really thought i would make money doing what i love. we created legalzoom to help people start their business and launch their dreams. go to legalzoom.com today and make your business dream a reality. at legalzoom.com we put the law on your side. you can't breathe through your nose, suddenly, you're a mouth breather. a mouth breather! well, put on a breathe right strip and shut your mouth. cold medicines open your nose over time, but add a breathe right strip and pow, it opens your nose up to 38% more. so you can breathe and do the one thing you want to do, sleep.